United Therapeutics Co. (NASDAQ:UTHR) Position Trimmed by Investment Management Corp of Ontario

Investment Management Corp of Ontario lessened its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 11,626 shares of the biotechnology company’s stock after selling 228 shares during the period. Investment Management Corp of Ontario’s holdings in United Therapeutics were worth $4,166,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of United Therapeutics by 1.6% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock valued at $652,000 after purchasing an additional 33 shares during the period. Toronto Dominion Bank boosted its holdings in shares of United Therapeutics by 0.8% in the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after buying an additional 37 shares during the period. ClariVest Asset Management LLC increased its position in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in shares of United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 42 shares during the period. Finally, First Citizens Bank & Trust Co. lifted its position in shares of United Therapeutics by 1.8% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock valued at $961,000 after acquiring an additional 48 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

UTHR has been the topic of several research analyst reports. Argus lifted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Jefferies Financial Group increased their price objective on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. HC Wainwright lifted their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company upped their target price on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Stock Down 0.4 %

Shares of UTHR opened at $368.79 on Wednesday. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The company’s fifty day moving average is $368.07 and its 200-day moving average is $336.78. The firm has a market cap of $16.47 billion, a price-to-earnings ratio of 16.20, a price-to-earnings-growth ratio of 1.08 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same period in the prior year, the business posted $5.38 earnings per share. The business’s quarterly revenue was up 22.9% on a year-over-year basis. As a group, research analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 7,796 shares of the firm’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $354.04, for a total value of $2,760,095.84. Following the transaction, the chief financial officer now directly owns 4,264 shares in the company, valued at approximately $1,509,626.56. This trade represents a 64.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Michael Benkowitz sold 15,000 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total transaction of $6,021,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $1,034,510.88. This represents a 85.34 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 119,442 shares of company stock valued at $44,577,770. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.